Inactive Instrument

Press Releases Algeta ASA

Equities

ALGETA

NO0010239437

Press Releases

Unlock all the news: Be the first to know and act before the market!

Algeta ASA : Algeta to host Capital Markets Days	18/11/13	PU
Algeta ASA : CORRECTION: Algeta ASA : Algeta Results for the Third Quarter 2013	08/11/13	PU
Algeta ASA : Algeta's Financial Calendar 2014	08/11/13	PU
Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	05/11/13	PU
Algeta ASA : Algeta Schedules Third Quarter 2013 Results Presentation, Webcast and Conference Call	28/10/13	PU
Algeta ASA : New data and analyses from the phase III ALSYMPCA trial of radium Ra 223 dichloride to be presented at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013	12/09/13	PU
Algeta ASA : Algeta results for the First Half and Second Quarter 2013	28/08/13	PU
Algeta ASA : Algeta Appoints Dr Andreas Menrad as Chief Scientific Officer	19/08/13	PU
Algeta ASA : Algeta schedules first half and second quarter 2013 results presentation, webcast and conference call	19/08/13	PU
Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	12/08/13	PU
Algeta ASA : Algeta celebrates the official opening of its commercial production facility for Xofigo® (radium Ra 223 dichloride) at the Institute for Energy Technology (IFE) in Norway	20/06/13	PU
Algeta ASA : Algeta to evaluate novel Targeted Thorium Conjugate (TTC) based on Avipep's Avibody platform	11/06/13	PU
Algeta ASA : Algeta announces first sale of Xofigo® (radium Ra 223 dichloride) in the United States	30/05/13	PU
Algeta ASA : New data and analyses from clinical trials of Xofigo® (radium-223 dichloride) to be presented at ASCO	16/05/13	PU
Algeta ASA : Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA	15/05/13	PU
Algeta ASA : Algeta results for the first quarter 2013	15/05/13	PU
Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	14/05/13	PU
Algeta ASA : Algeta schedules first quarter 2013 results presentation, webcast and conference call	07/05/13	PU
Algeta ASA : Algeta exercises option and signs exclusive license agreement with Lumiphore, Inc. for novel technology for development of Targeted Thorium Conjugates (TTCs)	02/05/13	PU
Algeta ASA : Algeta to Participate in Upcoming Investor Conference	17/04/13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Algeta ASA

Equities

ALGETA

NO0010239437

Press Releases

Filters